Lauterbach S, Kostev K, Kohlmann T: Prevalence of diabetic foot syndrome and its risk factors in the UK. J Wound Care 19: 333, 2010.
Boulton A, Vileikyte L, Ragnarson-Tennvall G, et al: The global burden of diabetic foot disease. Lancet 366: 1719, 2005.
Frykberg RG: Diabetic foot ulcers: pathogenesis and management. Am Fam Physician 66: 1655, 2002.
Christman AL, Selvin E, Margolis DJ, et al: Hemoglobin A1c predicts healing rate in diabetic wounds. J Invest Dermatol 131: 2121, 2011.
Galea AM, Springett K, Bungay H, et al: Incidence and location of diabetic foot ulcer recurrence. Diabet Foot J 12: 181, 2009.
World Health Organization: Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Available at: http://www.who.int/diabetes/publications/report-hba1c_2011.pdf. Accessed February 20, 2013.
International Working Group on the Diabetic Foot: The 2015 IWGDF guidance on the prevention and management of foot problems in diabetes. Available at: http://www.iwgdf.org/files/2015/website_development.pdf. Accessed May 25, 2017.
Apelqvist J, Bakker K, Van Houtum WH, et al: Practical guidelines in the management and prevention of the diabetic foot, based upon the International Consensus on the Diabetic Foot (2007). Diabetes Metab Res Rev 24(suppl 1): S181, 2008.
Rooke TW, Hirsch AT, Misra S, et al: ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 58: 2020, 2011.
Gethin GT, Cowman S: Wound measurement: the contribution to practice. Eur Wound Manage Assoc J 7: 26, 2007.
Edmonds ME, Foster AVM: Diabetic foot ulcers. BMJ 332: 407, 2006.
Merriman LM, Turner W, eds: Assessment of the Lower Limb, 2nd Ed, Elsevier Science Ltd, Edinburgh, Scotland, 2006.
Brem H, Tomic-Canic M: Cellular and molecular basis of wound healing in diabetes. J Clin Invest 117: 1219, 2007.
Lan CC, Liu IH, Fang AH, et al: Hyperglycaemic conditions decrease cultured keratinocyte mobility: implications for impaired wound healing in patients with diabetes. Br J Dermatol 159: 1103, 2008.
Margolis DJ, Kantor J, Santanna J, et al: Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol 136: 1531, 2000.
Markuson M, Hanson D, Anderson J, et al: The relationship between hemoglobin A(1c) values and healing time for lower extremity ulcers in individuals with diabetes. Adv Skin Wound Care 22: 365, 2009.
Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977, 1993.
UK Prospective Diabetes Study Group: Intensive blood group with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837, 1998.
Jabbar A, Contractor Z, Ebrahim MA, et al: Standard of knowledge about their disease among patients with diabetes in Karachi, Pakistan. J Pak Med Assoc 51: 216, 2001.
Muntner P, Wildman RP, Reynolds K, et al: Relationship between HbA1c level and peripheral arterial disease. Diabetes Care 28: 1981, 2005.
Sabanayagan C, Liew G, Tai ES, et al: Relationship between glycated haemoglobin and microvascular complications: is there a cut-off point for diagnosis of diabetes? Diabetologia 52: 1279, 2009.
We sought to evaluate the relationship between baseline hemoglobin A1c (HbA1c) level and clinical outcomes, including foot ulcer outcome (resolved versus unresolved) and wound-healing time, in individuals with type 2 diabetes.
A prospective observational study was conducted on 99 patients presenting with a diabetic foot ulceration. Patient and ulcer characteristics were recorded. Patients were followed up for a maximum of 1 year.
After 1 year of follow-up, 77% of ulcers healed and 23% did not heal. Although this study demonstrated that the baseline HbA1c reading was not a significant predictor of foot ulcer outcome (P = .603, resolved versus amputated), on further statistical analyses, when HbA1c was compared with the time taken for complete ulcer healing in the resolved group (n = 77), it proved to be significant (P = .009).
These findings have important implications for clinical practice, especially in an outpatient setting. Improving glycemic control may improve ulcer outcomes. Prediction of outcome may be helpful for health-care professionals in individualizing and optimizing clinical assessment and management of patients. Identification of determinants of outcome could result in improved health outcomes, improved quality of life, and fewer diabetes-related foot complications.